Updated MRA in the area of market access, coordinated market surveillance, information exchange and mutual recognition of compliance assessments are based on the Mutual Recognition Agreement (MRA), which is part of bilateral agreements I. A new revision of the MRA in the field of medical devices in bilateral agreements, which was last revised at the end of 2017, is a precondition for the full implementation of the new regulations on medical devices. With respect to the MRA agreement, products regulated as NHPs in Canada are covered by this MRA if they are manufactured to a GMP standard equivalent to that of drugs. Although not limited to the following, these mainly contain certain commercial herbal, probiotic and vitamin/mineral drug products. At the same time, negotiations between the EU and Switzerland on an Institutional Framework Agreement (IFA) are stalled. There are signs that the EU could associate the successful conclusion of the IFA negotiations with its willingness to proceed with a revised NEW MRA. This raises the question of whether such a link would be compatible with the World Trade Organization(WTO) mutual recognition disciplines. During a transitional period, the authorities assess each other`s pharmaceutical legislation, guidelines and regulatory systems under the agreement. In the medical device sector, Switzerland and the European Union (EU) have entered into a Mutual Recognition Agreement (MRA). In accordance with this contract, each party accepts products manufactured by manufacturers established in the other party that comply with the other party`s technical requirements. This allows producers on both sides to market their products in a common market. As a result of changes to EU legislation in this area, Switzerland is revising its own rules. As a result of these changes, Switzerland and the EU must develop a revised MRA to avoid technical barriers to their trade in medical devices.

This agreement provides for the mutual recognition of the bodies authorized by the parties to issue certificates. In parallel with the legislative drafts themselves, the MRA must also be amended through negotiations within the Swiss-EU Joint Committee, so that reciprocal obligations can be anchored in international law. SECO is the leader in this process. Restrictions: Capacity determination applies to routine inspections. In the future, the following types of products and inspections may be included in the scope of the agreement pending further consideration: the MRA with Israel is an agreement on the assessment of compliance and approval of industrial products (ACAA). It is a specific type of MRI based on the alignment of the legal system and infrastructure of the country concerned with that of the EU. The Mutual Recognition Agreement (MRA) between the FDA and the European Union allows drug inspectors to rely on information from anti-drug inspections carried out within the other country`s borders. Under the Drug Safety and Safety Act passed in 2012, the FDA has the authority to enter into agreements on the recognition of drug inspections by foreign regulators when the FDA has found that these authorities are able to conduct inspections that correspond to the United States.